Lista de obras -

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 ⬇️

artículo científico publicado el 20 de marzo de 2013

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

artículo científico publicado en 2015

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

artículo científico publicado en 2018

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

artículo científico publicado en 2017

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

artículo científico publicado en 2010

A phase I study of indoximod in patients with advanced malignancies

artículo científico publicado en 2016

Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects

artículo científico publicado en 2020

Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project

artículo científico publicado en 2017

Comparisons of high versus low emergency department utilizers in sickle cell disease

artículo científico publicado en 2008

Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints

scientific article published on 02 September 2020

Daily assessment of pain in adults with sickle cell disease

artículo científico publicado en 2008

Daily home opioid use in adults with sickle cell disease: The PiSCES project

artículo científico publicado en 2015

Depression and anxiety in adults with sickle cell disease: the PiSCES project

artículo científico publicado en 2007

Do African American men have lower survival from prostate cancer compared with White men? A meta-analysis

artículo científico publicado en 2010

E2F1 amplication and genetic heterogeneity in melanoma

artículo científico publicado en 2006

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial

scientific article published on January 2017

Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells

artículo científico publicado en 2007

Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES Project

artículo científico publicado en 2006

Health related quality of life in sickle cell patients: the PiSCES project

artículo científico publicado en 2005

Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.

artículo científico publicado en 2002

Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment

artículo científico publicado en 2006

Inpatient pain management in sickle cell disease

artículo científico publicado en 2019

Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling

artículo científico publicado en 2007

Marijuana Use in Adults Living with Sickle Cell Disease

scientific article published on 01 July 2018

Medical marijuana certification for patients with sickle cell disease: a report of a single center experience

scientific article published on 01 August 2020

Oxidative Addition of the Dithiobis(formamidinium) Cation to Platinum(II) Chloro Am(m)ine Compounds: Studies on Structure, Spectroscopic Properties, Reactivity, and Cytotoxicity of a New Class of Platinum(IV) Complexes Exhibiting S-Thiourea Coordina

artículo científico publicado el 14 de agosto de 1996

Pain site frequency and location in sickle cell disease: the PiSCES project

scientific article published on 23 July 2009

Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PiSCES study

artículo científico publicado en 2007

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

artículo científico publicado en 2020

Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

artículo científico publicado en 2006

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma

scientific article published on 01 August 2019

Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical model ⬇️

artículo científico publicado el 1 de agosto de 2003

Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.

artículo científico publicado en 2006

Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors

scientific article published on 17 February 2009

Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

artículo científico publicado en 2002

Phase I study of pemetrexed with sorafenib in advanced solid tumors

artículo científico publicado en 2016

Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.

artículo científico publicado en 2002

Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms

artículo científico publicado en 2014

Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

artículo científico publicado en 2011

Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma ⬇️

artículo científico publicado el 13 de enero de 2013

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

artículo científico publicado en 2012

Phase II Trials Powered to Detect Tumor Subtypes ⬇️

artículo científico publicado el 7 de julio de 2011

Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project.

artículo científico publicado en 2017

Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse

artículo científico publicado en 2019

Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease

scientific article published on 29 July 2019

Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine

artículo científico publicado en 2005

The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy

artículo científico publicado en 2003

Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo

artículo científico publicado en 2008

Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth

artículo científico publicado en 2005

Understanding pain and improving management of sickle cell disease: the PiSCES study

artículo científico publicado en 2005

Urinary Cannabinoid Mass Spectrometry Profiles Differentiate Dronabinol from Cannabis Use

scientific article published on 11 August 2020

Use of an implantable drug delivery system for refractory chronic sickle cell pain

artículo científico publicado en 2005

Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program

scientific article published on 24 July 2020

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

artículo científico publicado en 2008

coucou

artículo científico publicado en 2003

Lista de obras de

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 ⬇️

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

A phase I study of indoximod in patients with advanced malignancies

Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects

Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project

Comparisons of high versus low emergency department utilizers in sickle cell disease

Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints

Daily assessment of pain in adults with sickle cell disease

Daily home opioid use in adults with sickle cell disease: The PiSCES project

Depression and anxiety in adults with sickle cell disease: the PiSCES project

Do African American men have lower survival from prostate cancer compared with White men? A meta-analysis

E2F1 amplication and genetic heterogeneity in melanoma

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial

Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells

Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES Project

Health related quality of life in sickle cell patients: the PiSCES project

Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.

Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment

Inpatient pain management in sickle cell disease

Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling

Marijuana Use in Adults Living with Sickle Cell Disease

Medical marijuana certification for patients with sickle cell disease: a report of a single center experience

Oxidative Addition of the Dithiobis(formamidinium) Cation to Platinum(II) Chloro Am(m)ine Compounds: Studies on Structure, Spectroscopic Properties, Reactivity, and Cytotoxicity of a New Class of Platinum(IV) Complexes Exhibiting S-Thiourea Coordina

Pain site frequency and location in sickle cell disease: the PiSCES project

Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PiSCES study

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma

Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical model ⬇️

Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.

Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors

Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

Phase I study of pemetrexed with sorafenib in advanced solid tumors

Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.

Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms

Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma ⬇️

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

Phase II Trials Powered to Detect Tumor Subtypes ⬇️

Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project.

Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse

Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease

Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine

The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy

Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo

Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth

Understanding pain and improving management of sickle cell disease: the PiSCES study

Urinary Cannabinoid Mass Spectrometry Profiles Differentiate Dronabinol from Cannabis Use

Use of an implantable drug delivery system for refractory chronic sickle cell pain

Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

coucou